(Total Views: 531)
Posted On: 03/22/2025 12:05:00 AM
Post# of 154807
Quote:
Fat on the liver is the start of MASH. I don’t think we can treat MASH on our own. Ohm can you chime in please. I’m curious as well.
In a short 14 week trial in a small patient population leronlimab at 350mg reduced liver fat by almost 6% with a statistical significance of p = .008. It did not prove statistically significant at 700mg quite possibly due to a skewed population between leronlimab and placebo. I believe leronlimab at 700mg would show superior results compared to 350mg absent that skew. Reducing fibrosis is our forte but it's no slouch at reducing fat either. A GLP-1 agonist would probably increase that level of fat reduction but at the expense of side effects.
The company promoting a combo may be a way to get a trial done at no charge and at least get it on the market for MASH.
(21)
(0)
